Solomon Moshkevich Sells 1,010 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,010 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $260.49, for a total value of $263,094.90. Following the completion of the sale, the insider directly owned 133,633 shares of the company’s stock, valued at approximately $34,810,060.17. The trade was a 0.75% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45.

Natera Trading Up 6.2%

Shares of NASDAQ:NTRA opened at $269.66 on Friday. The stock has a market capitalization of $38.62 billion, a PE ratio of -165.44 and a beta of 1.51. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04. The firm has a fifty day moving average price of $245.48 and a 200 day moving average price of $221.90.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and set a $249.00 price target on shares of Natera in a research note on Tuesday, May 12th. UBS Group set a $260.00 price objective on Natera in a research note on Wednesday, June 24th. Wolfe Research assumed coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. Sanford C. Bernstein initiated coverage on Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price for the company. Finally, Royal Bank Of Canada started coverage on Natera in a research report on Thursday, June 11th. They set an “outperform” rating and a $275.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $267.83.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Analyst sentiment remains favorable: Canaccord Genuity raised its price target to $330 and maintained a “buy” rating, while the broader analyst consensus is “Moderate Buy” with an average target of $267.83. Analyst and Natera market coverage
• Positive Sentiment: Institutional ownership and recent buying provide additional support. Major investors including Coatue Management, Wellington Management, Norges Bank, JPMorgan and AQR Capital Management increased their positions; institutions collectively own approximately 99.9% of the stock.
• Neutral Sentiment: CFO Michael Burkes Brophy sold 5,064 shares worth about $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for roughly $1.48 million. Because the sales were pre-arranged and intended to satisfy tax-withholding obligations, they are less likely to signal reduced management confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold shares under similar tax-related plans, while retaining sizable positions. Fesko’s latest sale involved 782 shares worth approximately $203,700. Fesko SEC filing
• Negative Sentiment: The concentration of insider selling could create modest short-term selling pressure and may prompt valuation concerns. Natera also trades at a high valuation relative to its earnings profile, with a negative trailing price-to-earnings ratio, although no new operational warning accompanied the filings.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Robinhood Asset Management LLC bought a new position in shares of Natera in the fourth quarter worth about $12,981,000. UBS Group AG lifted its position in shares of Natera by 19.4% during the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after purchasing an additional 71,355 shares during the last quarter. J. Safra Sarasin Holding AG bought a new stake in Natera during the 4th quarter valued at approximately $2,825,000. ABN Amro Investment Solutions grew its holdings in Natera by 44.6% in the 1st quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock valued at $1,869,000 after buying an additional 2,883 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in Natera by 286.8% in the 4th quarter. Teacher Retirement System of Texas now owns 65,717 shares of the medical research company’s stock valued at $15,055,000 after buying an additional 48,728 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.